acetylcysteine has been researched along with Chronic Progressive Multiple Sclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Graves, JS; Henry, RG; Mowry, EM; Nourbakhsh, B; Schoeps, VA; Stern, WA; Waubant, E; Zhang, L | 1 |
| Akula, A; Bischof, A; Henry, RG; Krysko, KM; Li, Y; Manguinao, M; Nguyen, K; Nourbakhsh, B; Revirajan, N; Waubant, E | 1 |
2 trial(s) available for acetylcysteine and Chronic Progressive Multiple Sclerosis
| Article | Year |
|---|---|
N-Acetyl Cysteine as a Neuroprotective Agent in Progressive Multiple Sclerosis (NACPMS) trial: Study protocol for a randomized, double-blind, placebo-controlled add-on phase 2 trial.
Topics: Acetylcysteine; Clinical Trials, Phase II as Topic; Disease Progression; Double-Blind Method; Humans; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Neuroprotective Agents; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
A pilot study of oxidative pathways in MS fatigue: randomized trial of N-acetyl cysteine.
Topics: Acetylcysteine; Adult; Aged; Double-Blind Method; Fatigue; Feasibility Studies; Female; Free Radical Scavengers; Humans; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Outcome Assessment, Health Care; Oxidative Stress; Pilot Projects | 2021 |